Ionis Pharmaceuticals
Trade Ionis Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.
IONS Key Statistics
Stock Snapshot
Ionis Pharmaceuticals(IONS) stock is priced at $52.00, giving the company a market capitalization of 9.66B. It carries a P/E multiple of -16.73.
As of 2026-09-06, Ionis Pharmaceuticals(IONS) stock has fluctuated between $50.71 and $58.98. The current price stands at $52.00, placing the stock +2.5% above today's low and -11.8% off the high.
Ionis Pharmaceuticals(IONS) shares are trading with a volume of 2.67M, against a daily average of 2.3M.
During the past year, Ionis Pharmaceuticals(IONS) stock moved between $50.01 at its lowest and $86.74 at its peak.
During the past year, Ionis Pharmaceuticals(IONS) stock moved between $50.01 at its lowest and $86.74 at its peak.
IONS News
...
Ionis Pharmaceuticals ( (IONS) ) has shared an announcement. On September 4, 2026, Ionis Pharmaceuticals reported that its partner Novartis’ Phase 3 Lp(a)HORIZ...
Technology Novartis, Ionis Tumble On Surprise Flop For Heart Drug Licensing Novartis (NVS) said late Friday its Ionis Pharmaceuticals (IONS)-partnered Lp(a) blo...
Analyst ratings
81%
of 27 ratingsMore IONS News
Ionis Pharmaceuticals (IONS) partner Novartis (NVS) announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did no...
The U.S. Food and Drug Administration has approved Zanvastro (zilganersen), manufactured by Ionis Pharmaceuticals Inc. (NASDAQ:IONS), for Alexander disease in a...
BMO Capital analyst David Lebowitz raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $61 from $60 and keeps a Market Perform rating on the share...
RBC Capital downgraded Ultragenyx (RARE) to Sector Perform from Outperform with a price target of $19, down from $40. The company announced that the Phase 3 Asp...
Ionis Pharmaceuticals stock has delivered a 60.7% gain over the past five years, yet current valuation checks using market multiples point to the shares screeni...
Analyst Salveen Richter of Goldman Sachs maintained a Hold rating on Ionis Pharmaceuticals, retaining the price target of $69.00. Salveen Richter has given his...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.